<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatic encephalopathy in adults: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatic encephalopathy in adults: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatic encephalopathy in adults: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatic encephalopathy describes a spectrum of potentially reversible neuropsychiatric abnormalities seen in patients with liver dysfunction and/or portosystemic shunting. Overt hepatic encephalopathy develops in 30 to 45 percent of patients with cirrhosis and in 10 to 50 percent of patients with transjugular intrahepatic portal-systemic shunts [<a href="#rid1">1,2</a>]. The International Society for Hepatic Encephalopathy and Nitrogen Metabolism consensus defines the onset of disorientation or asterixis as the onset of overt hepatic encephalopathy [<a href="#rid3">3</a>]. Some patients with hepatic encephalopathy have subtle findings that may only be detected using specialized tests, a condition known as minimal hepatic encephalopathy [<a href="#rid4">4-6</a>]. Minimal hepatic encephalopathy is seen in up to 80 percent of patients with cirrhosis [<a href="#rid7">7-13</a>].</p><p>Hepatic encephalopathy is often easy to detect in patients presenting with overt neuropsychiatric symptoms. It may be more difficult to detect in patients with chronic liver diseases who have mild signs of altered brain function, particularly if the underlying cause of the liver disease may be associated with neurologic manifestations (such as alcohol-associated liver disease or Wilson disease). </p><p>This topic will review the clinical manifestations and diagnosis of hepatic encephalopathy in adults. The pathogenesis and treatment of hepatic encephalopathy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1257.html" rel="external">"Hepatic encephalopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H152814304"><span class="h1">CATEGORIZATION AND GRADING</span><span class="headingEndMark"> — </span>Hepatic encephalopathy is categorized based on several factors: the severity of manifestations, the time course, and whether precipitating factors are present [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of manifestations </strong>– The severity of hepatic encephalopathy is graded based on the clinical manifestations  (<a class="graphic graphic_table graphicRef101898" href="/d/graphic/101898.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef70740" href="/d/graphic/70740.html" rel="external">figure 1</a>) [<a href="#rid14">14</a>] (see <a class="local">'Clinical manifestations'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimal: Abnormal results on psychometric or neurophysiological testing without clinical manifestations (see <a class="local">'Psychometric tests'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Grade I: Changes in behavior, mild confusion, slurred speech, disordered sleep</p><p class="bulletIndent2"><span class="glyph">•</span>Grade II: Lethargy, moderate confusion</p><p class="bulletIndent2"><span class="glyph">•</span>Grade III: Marked confusion (stupor), incoherent speech, sleeping but arousable</p><p class="bulletIndent2"><span class="glyph">•</span>Grade IV: Coma, unresponsive to pain</p><p></p><p class="bulletIndent1">Patients with grade I encephalopathy may have mild asterixis, whereas pronounced asterixis is seen in patients with grade II or III encephalopathy [<a href="#rid15">15</a>]. Asterixis is typically absent in patients with grade IV encephalopathy, who instead may demonstrate decorticate or decerebrate posturing.</p><p></p><p class="bulletIndent1">Patients with minimal or grade I hepatic encephalopathy are described as having covert hepatic encephalopathy, whereas patients with grade II to IV hepatic encephalopathy are described as having overt hepatic encephalopathy. The separation of minimal hepatic encephalopathy from grade I hepatic encephalopathy is important for clinical studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time course </strong>– The time course for hepatic encephalopathy can be episodic, recurrent (bouts of hepatic encephalopathy that occur within a time interval of six months or less), or persistent (a pattern of behavioral alterations that are always present, interspersed with episodes of overt hepatic encephalopathy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitating factors </strong>–<strong> </strong>Episodes of hepatic encephalopathy are described as being either nonprecipitated or precipitated. If precipitated, the precipitating factors should be specified  (<a class="graphic graphic_table graphicRef50440" href="/d/graphic/50440.html" rel="external">table 2</a>). (See <a class="local">'Evaluation for precipitating causes'</a> below.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Hepatic encephalopathy is characterized by cognitive deficits and impaired neuromuscular function  (<a class="graphic graphic_figure graphicRef70740" href="/d/graphic/70740.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef58163" href="/d/graphic/58163.html" rel="external">figure 2</a>). Patients with minimal hepatic encephalopathy have subtle cognitive deficits, often appear to be asymptomatic, and may only be detected with psychomotor or electrophysiologic testing. Patients with overt hepatic encephalopathy have signs and symptoms that can be detected clinically, without the use of psychomotor testing (though psychomotor testing may be helpful in evaluating patients with mild encephalopathy).</p><p>In addition to the clinical manifestations of hepatic encephalopathy, patients frequently have clinical manifestations of chronic liver disease.</p><p class="headingAnchor" id="H335422231"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Cognitive findings in patients with hepatic encephalopathy vary from subtle deficits that are not apparent without specialized testing (minimal hepatic encephalopathy), to more overt findings, with impairments in attention, reaction time, and working memory  (<a class="graphic graphic_figure graphicRef70740" href="/d/graphic/70740.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef58163" href="/d/graphic/58163.html" rel="external">figure 2</a>) [<a href="#rid16">16</a>]. Patients with severe hepatic encephalopathy may progress to hepatic coma. </p><p>Disturbances in the diurnal sleep pattern (insomnia and hypersomnia) are common initial manifestations of hepatic encephalopathy and typically precede other mental status changes or neuromuscular symptoms. As hepatic encephalopathy progresses, patients may develop mood changes (euphoria or depression), disorientation, inappropriate behavior, somnolence, confusion, and unconsciousness.</p><p>Neuromuscular impairment in patients with overt hepatic encephalopathy includes bradykinesia, asterixis (flapping motions of outstretched, dorsiflexed hands), slurred speech, ataxia, hyperactive deep tendon reflexes, and nystagmus. Less commonly, patients develop loss of reflexes, transient decerebrate posturing, and coma. </p><p>Focal neurologic deficits may also be present. In a report of 32 patients who had 46 episodes of hepatic encephalopathy, a focal neurologic sign was detected in eight patients (17 percent of the episodes) [<a href="#rid17">17</a>]. The most common was hemiplegia. None of the patients with focal neurologic signs had abnormal findings on computed tomography scan or cerebrospinal fluid examination. Cerebral magnetic resonance imaging was performed in five of the eight patients and was normal in all five. Similarly, five patients with focal neurologic signs underwent Doppler ultrasound of the neck and vessels. In all five, the Doppler imaging was normal. The focal neurologic deficits resolved completely in seven of eight surviving patients after six months of follow-up.</p><p>Patients with hepatic encephalopathy usually have advanced chronic liver disease (decompensated cirrhosis) and thus have many of the physical stigmata associated with severe hepatic dysfunction. Physical findings may include muscle wasting, jaundice, ascites, palmar erythema, edema, spider telangiectasias, and fetor hepaticus. Some of these findings (such as muscle wasting, spider telangiectasias, and palmar erythema) are usually absent in previously healthy patients with acute hepatic failure since their development requires a relatively longer period of hepatic dysfunction. (See  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/3574.html" rel="external">"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p>Sarcopenia is a syndrome of decreased muscle mass, strength, and function that has been identified as a risk factor for hepatic encephalopathy, and this is possibly related to impaired detoxification of ammonia [<a href="#rid18">18</a>]. In a meta-analysis of five studies including 1713 patients with cirrhosis, sarcopenia was associated with higher risk of mild and overt hepatic encephalopathy compared with no sarcopenia (pooled odds ratio [OR] 3.34, 95% CI 1.68-6.67 and OR 2.05, 95% CI 1.28-3.29, respectively) [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Laboratory abnormalities</span><span class="headingEndMark"> — </span>Laboratory abnormalities in patients with hepatic encephalopathy may include elevated arterial and venous ammonia concentrations. In addition, patients typically have abnormal liver biochemical and synthetic function tests due to underlying liver disease. Patients may also have electrolyte disturbances (such as hyponatremia and hypokalemia) related to hepatic dysfunction and/or diuretic use. (See <a class="local">'Ammonia'</a> below and  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Laboratory findings'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The approach to the diagnosis of hepatic encephalopathy includes:</p><p class="bulletIndent1"><span class="glyph">●</span>A history and physical examination to detect the cognitive and neuromuscular impairments that characterize hepatic encephalopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of other causes of mental status changes (see <a class="local">'Differential diagnosis'</a> below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum laboratory testing to rule out metabolic abnormalities.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A computed tomography (CT) scan of the brain if the clinical findings suggest another cause for the patient's findings may be present (such as a subdural hematoma from trauma); a CT scan may also demonstrate cerebral edema (found in 80 percent of patients with acute hepatic encephalopathy) (see  <a class="medical medical_review" href="/d/html/1661.html" rel="external">"Acute toxic-metabolic encephalopathy in adults", section on 'Hepatic encephalopathy'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for possible precipitating causes of the hepatic encephalopathy (see <a class="local">'Evaluation for precipitating causes'</a> below).</p><p></p><p>While arterial and venous ammonia concentrations are often elevated in patients with hepatic encephalopathy, an elevated ammonia level is not required to make the diagnosis. In addition, elevated ammonia levels may be seen in patients who do not have hepatic encephalopathy  (<a class="graphic graphic_table graphicRef57620" href="/d/graphic/57620.html" rel="external">table 3</a>).</p><p>For patients with mild degrees of hepatic encephalopathy (minimal hepatic encephalopathy or grade I encephalopathy) in whom the diagnosis is unclear, psychometric and electrophysiologic tests may be helpful. In such patients, our approach is to first to ask about subtle signs of impaired mental status, and if signs point to the possible presence of minimal hepatic encephalopathy to perform psychometric testing (typically the number connection test)  (<a class="graphic graphic_algorithm graphicRef90152" href="/d/graphic/90152.html" rel="external">algorithm 1</a>). An alternative but less sensitive test is the Mini-Mental State Examination (MMSE). (See  <a class="medical medical_review" href="/d/html/14067.html" rel="external">"The mental status examination in adults", section on 'Cognitive screening tests'</a>.) </p><p>For patients with more severe hepatic encephalopathy (grades III and IV), the Glasgow Coma Scale may be useful for further stratifying the severity of neurologic impairment  (<a class="graphic graphic_figure graphicRef70740" href="/d/graphic/70740.html" rel="external">figure 1</a>) [<a href="#rid20">20</a>]. (See <a class="local">'Psychometric tests'</a> below and <a class="local">'Electrophysiologic tests'</a> below and <a class="local">'Clinical manifestations'</a> above.) </p><p class="headingAnchor" id="H152814945"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The evaluation should start by inquiring about mental status changes, keeping in mind that in patients with minimal hepatic encephalopathy the signs may be subtle. Patients should be asked about changes in their sleep patterns and in cognitive capacity (decreased attention span, impaired short term memory) leading to difficulties with normal daily activities. Patients should also be asked about impaired work performance and work- or driving-related accidents. Patients should also be examined for signs of neuromuscular dysfunction. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H152814968"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Ammonia is the best characterized neurotoxin that precipitates hepatic encephalopathy. However, an elevated serum ammonia concentration is not required to make the diagnosis and is not specific for hepatic encephalopathy. In addition, ammonia levels are influenced by factors such as how the blood sample is obtained and handled. Serum ammonia levels should <strong>not</strong> be used to screen for hepatic encephalopathy in patients who are asymptomatic or who have mental status changes in the absence of liver disease or a portal-systemic shunt. </p><p>Other routine laboratory tests should be obtained to exclude other causes of mental status changes (eg, hypoglycemia, uremia, electrolyte disturbances, and intoxication) and to look for conditions that may have precipitated the hepatic encephalopathy. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Evaluation for precipitating causes'</a> below.)</p><p class="headingAnchor" id="H152815085"><span class="h3">Ammonia</span><span class="headingEndMark"> — </span>The gastrointestinal tract is the primary source of ammonia, which enters the circulation via the portal vein. Ammonia is produced by enterocytes from glutamine and by colonic bacterial catabolism of nitrogenous sources, such as ingested protein and secreted urea. The intact liver clears almost all of the portal vein ammonia, converting it into urea or glutamine and preventing entry into the systemic circulation. The increase in blood ammonia levels in advanced liver disease is a consequence of impaired liver function and of shunting of blood around the liver. Muscle wasting may contribute since muscle is an important site for extrahepatic ammonia removal.</p><p>Whether to measure the serum ammonia concentration in patients suspected of having hepatic encephalopathy remains controversial. While the venous and arterial ammonia levels correlate with the severity of hepatic encephalopathy, levels are inconsistently elevated [<a href="#rid21">21,22</a>]. Measuring serum ammonia levels is not required to make the diagnosis of hepatic encephalopathy or for the long-term follow-up of patients with advanced chronic liver disease. Furthermore, ammonia levels can be elevated in a variety of nonhepatic conditions  (<a class="graphic graphic_table graphicRef57620" href="/d/graphic/57620.html" rel="external">table 3</a>).</p><p>Neither arterial or venous ammonia concentration is useful in screening for hepatic encephalopathy [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H152815106"><span class="h3">Other potential markers</span><span class="headingEndMark"> — </span>Serum levels of 3-nitrotyrosine may be elevated in patients with minimal hepatic encephalopathy. One study found that using a cutoff of 14 nM, 3-nitrotyrosine was 93 percent sensitive and 89 percent specific for detecting minimal hepatic encephalopathy [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Psychometric tests</span><span class="headingEndMark"> — </span>Commonly performed bedside tests are insufficiently sensitive to detect subtle changes in mental function. As a result, several psychometric tests have been evaluated that quantify the impairment of mental function in patients with mild stages of hepatic encephalopathy [<a href="#rid4">4,25-28</a>]. These tests are more sensitive for the detection of minor deficits of mental function than conventional clinical assessment or an EEG [<a href="#rid25">25</a>]. Several psychometric tests have been developed, but none is used routinely in clinical practice. Our approach is to use the number connection test if signs point to the possible presence of minimal hepatic encephalopathy.</p><p>The use of psychometric tests is limited because many are cumbersome and time consuming (up to two hours per session), their reliability is decreased by a learning effect when they are applied repeatedly, and there is poor correlation among the tests [<a href="#rid29">29,30</a>]. Another issue with psychometric tests is that they are nonspecific (ie, they cannot differentiate among multiple underlying conditions that may lead to similar test results) [<a href="#rid31">31</a>]. This is a particular problem in patients with alcohol-associated liver disease or Wilson disease since both are associated with central nervous system abnormalities. </p><p class="headingAnchor" id="H152815714"><span class="h3">Number connection test (Reitan Test)</span><span class="headingEndMark"> — </span>The most frequently used psychometric test is the number connection test (NCT or Reitan Test), which is easily administered and interpreted  (<a class="graphic graphic_figure graphicRef83108" href="/d/graphic/83108.html" rel="external">figure 3</a> and <a class="graphic graphic_figure graphicRef83109" href="/d/graphic/83109.html" rel="external">figure 4</a>) [<a href="#rid26">26,27,32</a>]. The NCT is a timed connect-the-numbers test. Patients without hepatic encephalopathy should finish the test in a number of seconds less than or equal to their age in years. In other words, if a patient is 50 years old, he should be able to finish the test in ≤50 seconds. </p><p>The test traditionally has two parts, but often only the first part of the test  (<a class="graphic graphic_figure graphicRef83108" href="/d/graphic/83108.html" rel="external">figure 3</a>) is used because the second part  (<a class="graphic graphic_figure graphicRef83109" href="/d/graphic/83109.html" rel="external">figure 4</a>) can be confusing and often does not add additional clinical information. </p><p class="headingAnchor" id="H152815729"><span class="h3">Other psychometric tests</span></p><p class="headingAnchor" id="H11"><span class="h2">Electrophysiologic tests</span><span class="headingEndMark"> — </span>Electrophysiologic tests to detect minimal hepatic encephalopathy include EEG monitoring, evoked potentials, and critical flicker frequency testing [<a href="#rid33">33-36</a>]. However, none of these tests is widely used. </p><p class="headingAnchor" id="H323876529"><span class="h3">Electroencephalogram (EEG) activity</span><span class="headingEndMark"> — </span>The evolving EEG changes associated with increasingly severe hepatic encephalopathy consist initially of a bilaterally synchronous decrease in wave frequency and an increase in wave amplitude, associated with the disappearance of a readily discernible normal alpha-rhythm (8 to 13 cps). The simplest EEG assessment of hepatic encephalopathy is grading the degree of abnormality of the conventional EEG tracing. A more refined assessment can be accomplished with computer-assisted spectral analysis of the EEG, which permits variables in the EEG (such as the mean dominant EEG frequency and the power of a particular EEG rhythm) to be quantified. Minor changes in the dominant EEG frequency occur in mild hepatic encephalopathy. Spectral EEG analysis may improve the assessment of mild hepatic encephalopathy by decreasing inter-operator variability and providing reliable parameters correlated with mental status [<a href="#rid33">33</a>].</p><p>The bispectral index (BIS) monitor is a rapid bedside tool to monitor EEG activity. In a prospective study, BIS monitoring was useful for grading and monitoring the degree of involvement of the central nervous system in patients with chronic liver disease and to classify the degree and progression of hepatic encephalopathy [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H152815307"><span class="h2">Radiologic imaging</span><span class="headingEndMark"> — </span>Radiologic imaging is primarily used to exclude other causes of mental status changes. We typically obtain a noncontrast head CT scan when the clinical findings suggest that another cause for the patient's mental status changes may be present (such as a subdural hematoma from trauma).</p><p class="headingAnchor" id="H14"><span class="h3">Computed tomography and magnetic resonance imaging of the brain</span><span class="headingEndMark"> — </span>A noncontrast CT scan is indicated in patients with overt hepatic encephalopathy in whom the diagnosis is uncertain, to exclude other diseases associated with coma or confusion. A CT scan may also reveal generalized or localized cerebral edema, suggesting a diagnosis of hepatic encephalopathy.</p><p class="headingAnchor" id="H323876558"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is superior to CT for the diagnosis of brain edema in liver failure, but it is not an established method for diagnosing hepatic encephalopathy. Changes have been observed on T1-weighted images with a strong signal in the basal ganglia in patients with hepatic encephalopathy, possibly due to manganese accumulation [<a href="#rid37">37</a>]. However, these changes are neither sensitive nor specific indicators of hepatic encephalopathy [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H343907868"><span class="h2">Evaluation for precipitating causes</span><span class="headingEndMark"> — </span>There are several conditions that may precipitate an episode of hepatic encephalopathy in patients with liver disease or a portal-systemic shunt  (<a class="graphic graphic_table graphicRef50440" href="/d/graphic/50440.html" rel="external">table 2</a>). These include [<a href="#rid16">16,40-43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Infection (including spontaneous bacterial peritonitis and urinary tract infections)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia and/or metabolic alkalosis</p><p class="bulletIndent1"><span class="glyph">●</span>Renal failure</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia</p><p class="bulletIndent1"><span class="glyph">●</span>Sedative or benzodiazepine use</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, hepatocellular carcinoma and/or vascular occlusion (hepatic vein or portal vein thrombosis)</p><p></p><p>Patients with hepatic encephalopathy should be evaluated for potential precipitating causes. This evaluation should include:</p><p class="bulletIndent1"><span class="glyph">●</span>A history to determine if the patient has been exposed to any medications or toxins (including alcohol)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination to look for signs of gastrointestinal bleeding or hypovolemia (see  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Bleeding manifestations'</a> and  <a class="medical medical_review" href="/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A search for sources of infection with blood and urine cultures, as well as paracentesis for patients with ascites (see  <a class="medical medical_review" href="/d/html/1249.html" rel="external">"Spontaneous bacterial peritonitis in adults: Diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine serum chemistries to look for metabolic and electrolyte abnormalities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum alpha-fetoprotein (see  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Alpha-fetoprotein'</a>)</p><p></p><p>     ●Urine drug screen. Some patients covertly use medications (eg, sedatives) that may precipitate hepatic encephalopathy requiring hospital admission.  </p><p class="headingAnchor" id="H335421073"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of patients presenting with mental status changes is long  (<a class="graphic graphic_table graphicRef59893" href="/d/graphic/59893.html" rel="external">table 4</a>). While hepatic encephalopathy should be considered in patients with acute or chronic liver disease or a portal-systemic shunt, particularly those with a history of hepatic encephalopathy, other causes for the patient's confusion should be considered, such as a subdural hematoma, renal failure, or mental status changes associated with the patient's underlying liver disease (eg, Wilson disease). </p><p>A general approach to the evaluation of patients with delirium and confusional status is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a>.)</p><p class="headingAnchor" id="H323875448"><span class="h1">CAPACITY TO DRIVE</span><span class="headingEndMark"> — </span>We advise patients to avoid driving following an episode of overt hepatic encephalopathy. For patients who want to resume driving, we advise them to contact their local department of motor vehicles for a driving assessment based on local regulations. We agree with guidance from professional societies that assessing the ability to drive should be done according to local regulations because psychometric tests cannot reliably determine if the patient is a safe driver [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H1348984808"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115541.html" rel="external">"Society guideline links: Cirrhosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/120002.html" rel="external">"Society guideline links: Adult with altered mental status in the emergency department"</a>.)</p><p class="headingAnchor" id="H24517674"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16979.html" rel="external">"Patient education: Hepatic encephalopathy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Hepatic encephalopathy describes the spectrum of potentially reversible neuropsychiatric abnormalities seen in patients with liver dysfunction. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Hepatic encephalopathy is characterized by cognitive deficits and impaired neuromuscular function  (<a class="graphic graphic_figure graphicRef70740" href="/d/graphic/70740.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef58163" href="/d/graphic/58163.html" rel="external">figure 2</a>). Cognitive findings in patients with hepatic encephalopathy vary from subtle deficits that are not apparent without specialized testing (minimal hepatic encephalopathy) to more overt findings, with impairments in attention, reaction time, and working memory. Patients with severe hepatic encephalopathy may progress to hepatic coma. Neuromuscular impairments include bradykinesia, hyperreflexia, rigidity, myoclonus, and asterixis. Disturbances in the diurnal sleep pattern (insomnia and hypersomnia) are common initial manifestations of hepatic encephalopathy and typically precede other mental status changes or neuromuscular symptoms. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Categorization and grading'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The approach to the diagnosis of hepatic encephalopathy includes  (<a class="graphic graphic_algorithm graphicRef90152" href="/d/graphic/90152.html" rel="external">algorithm 1</a>) (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history and physical examination to detect the cognitive and neuromuscular impairments that characterize hepatic encephalopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psychometric testing if minimal hepatic encephalopathy is suspected.</p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of other causes of mental status changes: Serum laboratory testing to rule out metabolic abnormalities, a computed tomography scan of the brain if the clinical findings suggest another cause for the patient's findings may be present (such as a subdural hematoma from trauma).</p><p></p><p class="bulletIndent1">While arterial and venous ammonia concentrations are often elevated in patients with hepatic encephalopathy, an elevated ammonia level is not required to make the diagnosis. In addition, elevated ammonia levels may be seen in patients who do not have hepatic encephalopathy  (<a class="graphic graphic_table graphicRef57620" href="/d/graphic/57620.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for precipitating causes </strong>– Patients with hepatic encephalopathy should be evaluated for potential precipitating causes  (<a class="graphic graphic_table graphicRef50440" href="/d/graphic/50440.html" rel="external">table 2</a>). This evaluation should include (see <a class="local">'Evaluation for precipitating causes'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history to determine if the patients have been exposed to any medications or toxins (including alcohol)</p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination to look for signs of gastrointestinal bleeding or hypovolemia</p><p class="bulletIndent2"><span class="glyph">•</span>A search for sources of infection with blood and urine cultures, as well as paracentesis for patients with ascites</p><p class="bulletIndent2"><span class="glyph">•</span>Routine serum chemistries to look for metabolic and electrolyte abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Serum alpha-fetoprotein</p><p class="bulletIndent2"><span class="glyph">•</span>Urine drug screen</p><p></p><p class="headingAnchor" id="H719867575"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Ferenci, MD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Romero-Gómez M, Boza F, García-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96:2718.</a></li><li><a class="nounderline abstract_t">Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41:386.</a></li><li><a class="nounderline abstract_t">Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009; 50:2014.</a></li><li><a class="nounderline abstract_t">Schomerus H, Hamster W, Blunck H, et al. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981; 26:622.</a></li><li><a class="nounderline abstract_t">Ortiz M, Córdoba J, Jacas C, et al. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol 2006; 44:104.</a></li><li><a class="nounderline abstract_t">Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138:2332.</a></li><li><a class="nounderline abstract_t">Maldonado-Garza HJ, Vázquez-Elizondo G, Gaytán-Torres JO, et al. Prevalence of minimal hepatic encephalopathy in cirrhotic patients. Ann Hepatol 2011; 10 Suppl 2:S40.</a></li><li><a class="nounderline abstract_t">Gad YZ, Zaher AA, Moussa NH, et al. Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab J Gastroenterol 2011; 12:58.</a></li><li><a class="nounderline abstract_t">Dhiman RK, Saraswat VA, Sharma BK, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 2010; 25:1029.</a></li><li><a class="nounderline abstract_t">Sharma P. Minimal hepatic encephalopathy. J Assoc Physicians India 2009; 57:760.</a></li><li><a class="nounderline abstract_t">Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian J Gastroenterol 2009; 28:5.</a></li><li><a class="nounderline abstract_t">Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14:3609.</a></li><li><a class="nounderline abstract_t">Amodio P, Marchetti P, Del Piccolo F, et al. Study on the Sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy. Metab Brain Dis 1998; 13:159.</a></li><li><a class="nounderline abstract_t">Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715.</a></li><li><a class="nounderline abstract_t">Gill RQ, Sterling RK. Acute liver failure. J Clin Gastroenterol 2001; 33:191.</a></li><li><a class="nounderline abstract_t">Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012; 16:301.</a></li><li><a class="nounderline abstract_t">Cadranel JF, Lebiez E, Di Martino V, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol 2001; 96:515.</a></li><li><a class="nounderline abstract_t">Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol 2017; 15:934.</a></li><li><a class="nounderline abstract_t">Wijarnpreecha K, Werlang M, Panjawatanan P, et al. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2020; 19:245.</a></li><li><a class="nounderline abstract_t">Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.</a></li><li><a class="nounderline abstract_t">Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114:188.</a></li><li><a class="nounderline abstract_t">Nicolao F, Efrati C, Masini A, et al. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 2003; 38:441.</a></li><li><a class="nounderline abstract_t">STAHL J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Intern Med 1963; 58:1.</a></li><li><a class="nounderline abstract_t">Montoliu C, Cauli O, Urios A, et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol 2011; 106:1629.</a></li><li><a class="nounderline abstract_t">Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978; 75:462.</a></li><li><a class="nounderline abstract_t">Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22:541.</a></li><li><a class="nounderline abstract_t">Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999; 29:1662.</a></li><li><a class="nounderline abstract_t">Amodio P, Marchetti P, Del Piccolo F, et al. Visual attention in cirrhotic patients: a study on covert visual attention orienting. Hepatology 1998; 27:1517.</a></li><li><a class="nounderline abstract_t">Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, et al. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut 2013; 62:1497.</a></li><li><a class="nounderline abstract_t">Ferenci P. Diagnosis of minimal hepatic encephalopathy: still a challenge. Gut 2013; 62:1394.</a></li><li><a class="nounderline abstract_t">Weissenborn K. Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions. J Clin Exp Hepatol 2019; 9:109.</a></li><li><a class="nounderline abstract_t">Weissenborn K, Rückert N, Hecker H, Manns MP. The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol 1998; 28:646.</a></li><li><a class="nounderline abstract_t">Amodio P, Marchetti P, Del Piccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999; 110:1334.</a></li><li><a class="nounderline abstract_t">Dahaba AA, Worm HC, Zhu SM, et al. Sensitivity and specificity of bispectral index for classification of overt hepatic encephalopathy: a multicentre, observer blinded, validation study. Gut 2008; 57:77.</a></li><li><a class="nounderline abstract_t">Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther 2013; 37:527.</a></li><li><a class="nounderline abstract_t">Yang SS, Wu CH, Chiang TR, Chen DS. Somatosensory evoked potentials in subclinical portosystemic encephalopathy: a comparison with psychometric tests. Hepatology 1998; 27:357.</a></li><li><a class="nounderline abstract_t">Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346:270.</a></li><li><a class="nounderline abstract_t">Thuluvath PJ, Edwin D, Yue NC, et al. Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy. Hepatology 1995; 21:440.</a></li><li><a class="nounderline abstract_t">Krieger S, Jauss M, Jansen O, et al. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996; 111:147.</a></li><li><a class="nounderline abstract_t">Mumtaz K, Ahmed US, Abid S, et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Physicians Surg Pak 2010; 20:514.</a></li><li><a class="nounderline abstract_t">Onyekwere CA, Ogbera AO, Hameed L. Chronic liver disease and hepatic encephalopathy: clinical profile and outcomes. Niger J Clin Pract 2011; 14:181.</a></li><li><a class="nounderline abstract_t">Maqsood S, Saleem A, Iqbal A, Butt JA. Precipitating factors of hepatic encephalopathy: experience at Pakistan Institute of Medical Sciences Islamabad. J Ayub Med Coll Abbottabad 2006; 18:58.</a></li><li><a class="nounderline abstract_t">Devrajani BR, Shah SZ, Devrajani T, Kumar D. Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad. J Pak Med Assoc 2009; 59:683.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="721713011e1d14141b1117321713011e1d14141b11175c1707">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol 2022; 77:807.</a></li></ol></div><div id="topicVersionRevision">Topic 1237 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11569701" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660434" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787808" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7249898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neuropsychological abnormalities in cirrhosis include learning impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178797" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22228880" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of minimal hepatic encephalopathy in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684474" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20594216" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20329443" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Minimal hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19529896" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Minimal hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595126" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Minimal hepatic encephalopathy matters in daily life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9699923" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Study on the Sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042402" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11500606" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541700" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232699" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816756" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31422030" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4136544" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Assessment of coma and impaired consciousness. A practical scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637132" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Correlation between ammonia levels and the severity of hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663235" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13978712" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483460" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/680502" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/868833" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347105" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620321" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Visual attention in cirrhotic patients: a study on covert visual attention orienting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297006" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23315503" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis of minimal hepatic encephalopathy: still a challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765943" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566834" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454268" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Spectral versus visual EEG analysis in mild hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698861" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sensitivity and specificity of bispectral index for classification of overt hepatic encephalopathy: a multicentre, observer blinded, validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293917" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462631" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Somatosensory evoked potentials in subclinical portosystemic encephalopathy: a comparison with psychometric tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7630246" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Manganese and chronic hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843718" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698193" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688015" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860136" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chronic liver disease and hepatic encephalopathy: clinical profile and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17591012" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Precipitating factors of hepatic encephalopathy: experience at Pakistan Institute of Medical Sciences Islamabad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19813682" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35724930" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
